Efficacy in MCL...7 pts with TP53 mutation had ORR of 85.7% with mPFS NR and 14 pts with Ki-67 ≥30% had ORR of 85.7% with mPFS 33.2 mos. Overall, median OS was NR (95% CI: 22.46, NE)...Zilo+Ibr is well-tolerated with a safety profile that is comparable to Ibr alone. AF (all grades) occurred in 9.4% of all pts treated which appears lower than rate in Ibr alone studies. The combination is very promising in pts with RR MCL (ORR 89.3%, CR 42.9%, mPFS NR). For CLL pts with TP53 mut/del(17p), Zilo+Ibr is also very active, maintaining 100% PFS and OS at ∼42 mos.

Patients (Pts) with relapsed or refractory (RR) MCL with ≥1 prior line of therapy (LOT) or treatment-naïve (TN) or RR CLL with ≥1 prior LOT were enrolled....For 6 pts with P53 mutations, the ORR was 83.3% (1 CR, 4 PRs), mDOR was 13.84 mos (11.93, NE), mPFS was 17.3 (95% CI: 2.85, NE) and LPFS at 12 mos was >80%.